Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to prevent recurrence and metastasis in cancer patients by targeting and eradicating cancer stem cells through the activation of ...

Secura Bio, Inc. ( an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced a poster presentation highlighting extended follow up analyses examining ...

Oslo, 4 November 2025: Reference is made to the stock exchange notice published by Zelluna ASA (the "Company") on 3 November 2025 regarding the successful private placement and retail offering.

AMT-143 is a long-acting local analgesic for postsurgical pain control. It is administered via instillation at the time of the surgery. In a Phase 1 study, AMT-143 demonstrated sustained release of ...

The UAB site joins the list of clinical centers participating in the Company’s global Phase 1/1b trial, which is designed to assess the safety, tolerability, pharmacokinetics (PK), and ...

MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its ...

Initial results of a Phase 1 / 2 open label study of AT-02, the company’s lead pan-amyloid removal therapeutic candidate, in patients with AL amyloidosis will be presented at ASH. The presentation ...

Purespring co-author paper with real world evidence on epidemiological prevalence data of NPHS2 pathogenic variants across global populations London – 4 November 2025 – Purespring Therapeutics, a ...

Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue ...

Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program. Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potent ...

Cash balance of $344.8 million as of September 30, 2025, together with net proceeds of ~$445 million from October 2025 equity offering, with expected runway into 2028 BEDFORD, Mass., Nov. 04, 2025 ...

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today is providing a number of strategic updates, including its recently executed option agreement with Incyte ...